3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Laryngeal Diseases
1
Infections
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
COVID-19
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Adenocarcinoma Of Esophagus
1
Interventions
Cisplatin
13
Cetuximab
10
Radiotherapy
7
pembrolizumab
4
Pemetrexed
4
Fluorouracil
4
Docetaxel
4
Gemcitabine
3
durvalumab
2
Surveys and Questionnaires
2
Radiotherapy, Intensity-Modulated
2
Nivolumab
2
Narrow Band Imaging
2
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
2
Gefitinib
2
Drug Therapy
2
Carboplatin
2
tremelimumab
1
niraparib
1
monalizumab
1
linrodostat
1
dostarlimab
1
capmatinib
1
X-Rays
1
Vitamin B 12
1
Tirapazamine
1
Tablets
1
Sugars
1
Radiotherapy, Adjuvant
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Laryngeal Diseases
×
monalizumab
×
Clear all
NCT04590963
2026-06-01
INTERLINK-1
AstraZeneca
Phase 3
Active not recruiting
370 enrolled
21 charts